FDA Says Studies By Panexcell And Synchron “Unacceptable”

US Agency Warns Pharmaceutical Companies Against Using Firms’ Data

 
• By Akriti Seth
  
lab
After conducting inspections at the facilities of Panexcell and Synchron, FDA finds data integrity issues • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Regulation

More from Policy & Regulation